Authors
Latest:
Evaluating Poseida Therapeutics' P-BCMA-ALLO1 With Optimized Lymphodepletion in R/R MyelomaBhagirathbhai R. Dholaria, MD, an associate professor of medicine in malignant hematology & stem cell transplantation at Vanderbilt University Medical Center, discussed new results presented at Tandem 2025.
Latest:
Nicole Paulk, PhD, on Applying AAV Approaches in OncologyThe CEO, founder, and president of Siren Biotechnology discussed the preclinical data she presented at ASGCT’s 2023 meeting on the use of AAV immuno-gene therapy for high-grade gliomas.
Latest:
ImmunoLogic, Episode 2: "Charting New Frontiers in CAR T-Cell Safety" With Bruce Levine, PhDIn Episode 2 of ImmunoLogic, Bruce Levine, PhD, discussed the current the risk-benefit-ratio for CAR-T therapy.
Latest:
Oncolytic Viruses are a Novel Delivery System in Malignant TumorsGenetically modified oncolytic viruses may provide a new strategy against malignant tumors.
Latest:
Holly Peay, PhD, on Patient Preference Research as a Means of Patient ExpressionThe senior research scientist at RTI International discussed how patient preference studies can help patients with rare diseases have their voices heard.
Latest:
Integrating TIL-Based Therapy into Melanoma Treatment: Omar Hamid, MDThe chief of translational Research and immunotherapy at The Angeles Clinic and Research Institute discussed the integration of tumor infiltrating lymphocyte–based therapy into the melanoma armamentarium.
Latest:
Geoffrey Hodge on Developing CAR T-Cell Therapies for Solid TumorsGeoffrey Hodge, chief executive officer of SOTIO Biotech US, discussed the company's development of the BOXR cell therapy platform.
Latest:
Xaviar Michael Jones, MD, on Expanding Horizons in RNA Therapeutics Through CollaborationThe postdoctoral research fellow at Cedars Sinai Medical Center discussed the future of RNA therapy in the context of research in systemic sclerosis he presented at AHA’s Scientific Sessions 2023.
Latest:
Benjamin L. Schlechter, MD, on TAC01-HER2 in HER2-Positive Solid TumorsSchlechter discussed the potential advantages of TAC01-HER2 over current standards of care.
Latest:
A Review of Autologous Stem Cell Transplantation in AmyloidosisIuliana Vaxman, MD, and Angela Dispenzieri, MD, review eligibility criteria for ASCT in AL amyloidosis, conditioning dosing, efficacy in terms of hematologic and organ response, and future areas of research.
Latest:
Michel Michaelides, MD, FACP, on Gene Therapy's Potential in Retinitis PigmentosaThe professor of ophthalmology at the University College London Institute of Ophthalmology discussed the likely rise of gene therapies in inherited retinal diseases.
Latest:
ACGT's Highlights From the International Oncolytic Virotherapy ConferenceTake a look back at the 2023 conference, hosted by the University of Calgary and McMaster University, and held in Banff, Alberta, Canada.
Latest:
Andras Heczey, MD, on Antitumor Activity of CAR NKTs in Solid TumorsThe director of the Liver Tumor Program at Texas Children’s Hospital discussed a phase 1 study of CAR NK T-cells in neuroblastoma.
Latest:
Cilta-cel Garners More Positive Data in Early and Late Relapsed Multiple Myeloma TreatmentYing Huang, chief executive officer, Legend Biotech, discussed new data from the CARTIFAN-1 and CARTITUDE-2 studies.
Latest:
David Rawlings, MD, on the Potential of Engineered Treg Cells to Treat Autoimmune DiseasesThe director of the Center for Immunity and Immunotherapies at Seattle Children's Research Institute discussed preclinical research on overcoming limitations of Treg cells through genetic engineering.
Latest:
Samer Srour, MB ChB, MS, on Improving CAR T-Cell Therapy for Solid TumorsThe assistant professor of stem cell transplantation at MD Anderson Cancer Center discussed positive data in ccRCC that he believes should excite the solid tumor field as a whole.
Latest:
Advantages of Manufacturing Cell Therapies In-HouseThe chief technology and chief executive officer of Mustang Bio discussed the company’s integrated approach to drug development.
Latest:
Mustafa Turkoz, PhD, on Rejuvenating Immune Cells With ERA ReprogrammingThe head of immunology at Turn Biotechnologies discussed preclinical data demonstrating proof-of-concept with the company’s epigenome reprogramming platform.
Latest:
Gene Therapy for Sickle Cell DiseaseExperts discuss the safety profile and cost of gene therapy for the management of sickle cell disease.
Latest:
Mary “Nora” Disis, MD, on Reevaluating the Potential of CAR-T Approaches in Ovarian CancerThe director of University of Washington Medicine’s Cancer Vaccine institute discussed the importance of continuing to develop new CAR-T approaches in the ovarian cancer field despite initial setbacks.
Latest:
Electrotransfection: A Different Approach to Plasmid DeliveryThe chief scientific officer and chief medical officer at Eyevensys discuss the biotech company's pipeline and approach to gene therapy.
Latest:
Sebastian Michels, MD, on the Role of Alternative Polyadenylation in ALS Disease PathogenesisThe postdoctoral fellow and member of the La Spada Lab at University of California, Irvine, discussed findings he presented at ANA’s 2023 conference that may have implications for future RNA therapy development.
Latest:
Improving Speed and Fidelity of CRISPR/Cas9: Kenneth Johnson, PhD, and David Taylor, PhDThe professors and researchers from The University of Texas at Austin discussed new findings of Cas9 structure and mechanisms.
Latest:
Working With the Community to Improve Patient Access to Trials, TherapiesRob Richards, administrative director, cell therapy and transplant, University of Pennsylvania, discussed improving reach of gene therapy trials and therapies.
Latest:
Expediting the Development of Patient-Specific iSPC Cell TherapiesStefan Braam, PhD, chief executive officer of Ncardia and Cellistic discussed the companies’ work in the cell therapy space.
Latest:
Leigh Ramos-Platt, MD, on Looking Forward to Gene Therapy’s GrowthThe clinical professor of neurology and pediatrics at Keck School of Medicine of USC also discussed current strategies with gene therapy administration.
Latest:
Roger Hajjar, MD, on Gene Therapy as a Novel Precision Medicine Modality in CardiologyThe director of the Mass General Brigham Gene and Cell Therapy Institute shared his main message for cardiologists at the American Heart Association’s Scientific Sessions 2023.
Latest:
Susan Bal, MD, on Promising Efficacy With GPRC5D-CAR Therapy in R/R Multiple MyelomaThe assistant professor of medicine at University of Alabama – Birmingham discussed efficacy findings on BMS-986983 and more research to be done.
Latest:
NK Cell Therapy Potential in Treating COVID-19 and Other VirusesAllen Feng, PhD, chief scientific officer, HebeCell, discussed the company’s NK cell technologies.
Latest:
The Future of Gene Therapies in Inherited Retinal DiseasesMariya Moosajee, MBBS, BSc, PhD, FRCOphth, discussed the next generation of gene therapy for inherited retinal diseases.
